Pharmacological studies of the opioids, mood stabilizer and dopaminergic drugs on pilocarpine-induced seizures and status epilepticus

被引:7
作者
Freitas, R. M.
Vasconcelos, S. M. M.
Sousa, F. C. F.
Viana, G. S. B.
Fonteles, M. M. F.
机构
[1] Univ Fed Ceara, Dept Pharm, Fac Pharm Dent & Nursing, BR-60000000 Fortaleza, Ceara, Brazil
[2] Univ Fed Ceara, Dept Physiol & Pharmacol, Neuropharmacol Lab, Sch Med, BR-60431970 Fortaleza, Ceara, Brazil
关键词
pilocarpine; seizures; status epilepticus; SCH; 23390; haloperidol; morphine;
D O I
10.1016/j.neulet.2006.08.009
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
This work was designed to study the influence of drugs during seizures and status epilepticus (SE) induced by pilocarpine and mortality in adult rats. Morphine (0.1 and 0.2 mg/kg), SCH 23390 (0.1 and 0.2 mg/kg), haloperidol (5 and 10 mg/kg) and lithium (30 and 60 mg/kg) were administered intraperitoneally (i.p.), 30 min before to pilocarpine (400 mg/kg, s.c.). The animals were observed (24 h) to determine: number of peripheral cholinergic signs, tremors, stereotyped movements, seizures, SE, latency to first seizure and number of deaths after pilocarpine treatment. Morphine and haloperidol had proconvulsant effects in both doses tested. Smaller and higher doses of these drugs no protected and increased pilocarpine-induced seizures, SE and/or mortality. SCH 23390 protected against seizures, increased the latency to first seizure and reduced the mortality of the animals treated with pilocarpine Theses results suggest that dopamine receptor system receptor subtypes exert opposite functions on the regulation of convulsive activity. The morphine is proconvulsant in lower doses. The opioids in high doses tested exert an action proconvulsant during the establishment of epileptic activity induce by pilocarpine. The lithium no protected the animals against seizures induced by pilocarpine and is used which a model of epilepsy associated with lower doses of pilocarpine in several studies, suggesting absence of the effect anticonvulsants in rodents. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:84 / 88
页数:5
相关论文
共 27 条
[1]  
Alldredge BK, 1999, NEUROLOGY, V53, pS68
[2]   DOPAMINE-D1 AND DOPAMINE-D2 RECEPTORS MEDIATE OPPOSITE FUNCTIONS IN SEIZURES INDUCED BY LITHIUM-PILOCARPINE [J].
BARONE, P ;
PALMA, V ;
DEBARTOLOMEIS, A ;
TEDESCHI, E ;
MUSCETTOLA, G ;
CAMPANELLA, G .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 195 (01) :157-162
[3]   DOPAMINE-D1 RECEPTOR MODULATION OF PILOCARPINE-INDUCED CONVULSIONS [J].
BARONE, P ;
PARASHOS, SA ;
PALMA, V ;
MARIN, C ;
CAMPANELLA, G ;
CHASE, TN .
NEUROSCIENCE, 1990, 34 (01) :209-217
[4]  
BARONE P, 1990, BASAL GANGLIA, V3, P568
[5]   SIMILAR BEHAVIORAL-EFFECTS OF SIGMA-AGONISTS AND PCP-LIKE NONCOMPETITIVE NMDA ANTAGONISTS IN GUINEA-PIGS [J].
BRENT, PJ .
PSYCHOPHARMACOLOGY, 1991, 105 (03) :421-427
[6]   Primary care: Epilepsy. [J].
Browne, TR ;
Holmes, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (15) :1145-1151
[7]   THE FUNCTIONAL-ANATOMY AND PATHOLOGY OF LITHIUM PILOCARPINE AND HIGH-DOSE PILOCARPINE SEIZURES [J].
CLIFFORD, DB ;
OLNEY, JW ;
MANIOTIS, A ;
COLLINS, RC ;
ZORUMSKI, CF .
NEUROSCIENCE, 1987, 23 (03) :953-968
[8]   Chronic treatment with fluoxetine decreases seizure threshold in naive but not in rats exposed to the learned helplessness paradigm:: Correlation with the hippocampal glutamate release [J].
Ferrero, AJ ;
Cereseto, M ;
Reinés, A ;
Bonavita, CD ;
Sifonios, LL ;
Rubio, MC ;
Wikinski, SI .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2005, 29 (05) :678-686
[9]   Monoamine levels after pilocarpine-induced status epilepticus in hippocampus and frontal cortex of Wistar rats [J].
Freitas, RM ;
Vasconcelos, SMM ;
Souza, FCF ;
Viana, GSB ;
Fonteles, MMF .
NEUROSCIENCE LETTERS, 2004, 370 (2-3) :196-200
[10]   Pilocarpine-induced status epilepticus in rats: lipid peroxidation level, nitrite formation, GABAergic and glutamatergic receptor alterations in the hippocampus, striatum and frontal cortex [J].
Freitas, RM ;
Sousa, FCF ;
Vasconcelos, SMM ;
Viana, GSB ;
Fonteles, MMF .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2004, 78 (02) :327-332